SCHEMBL40708

SCHEMBL40708

NC(=O)N1C=CC=CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperazine SCHEMBL28135603 0.90
Pyrrole SCHEMBL28201580 0.87
SCHEMBL8865924 0.85
SCHEMBL30587626 0.85
Imidazole SCHEMBL28194578 0.81 ALDH1A1 (0.41)
Hydrazine SCHEMBL28121587 0.79
SCHEMBL14693703 0.79 TSHR (0.47)
SCHEMBL29614489 0.79
SCHEMBL1042812 0.78
SCHEMBL28246000 0.78 SMN1; SMN2 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 712 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4305029-A1 NEW 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-01-17 EP claimed
WO-2022189392-A1 NEW 2,3-DIHYDRO-1H-PYRROLO[3,2-b]PYRIDINE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-09-15 WO claimed
CN-110022875-A Therapeutic inhibiting compound 莱福斯希医药公司 2019-07-16 CN claimed
CN-109310675-A Therapeutic inhibiting compound 莱福斯希医药公司 2019-02-05 CN claimed
CN-107531660-A α cinnamide compounds and composition as HDAC8 inhibitor 福马治疗股份有限公司 2018-01-02 CN claimed
CN-104302287-B Indolin-2-one derivatives as protein kinase inhibitors 安基生技新药股份有限公司 2017-12-26 CN claimed
CN-103764140-B Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases 韩国化学研究院 2017-05-17 CN claimed
WO-2016095089-A1 ERK INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-23 WO claimed
EP-2900671-A1 SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES Bayer Pharma Aktiengesellschaft (DE) 2015-08-05 EP claimed
EP-2900670-A1 SUBSTITUTED INDAZOL-PYRROLOPYRIMIDINES USEFUL IN THE TREATMENT OF HYPERFOLIFERATIVE DISORDERS Bayer Pharma Aktiengesellschaft (DE) 2015-08-05 EP claimed
EP-2838898-A1 SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF Advinus Therapeutics Limited (IN) 2015-02-25 EP claimed
WO-2015011008-A1 7-AZAINDOLE DERIVATIVES AS PARP INHIBITORS SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2015-01-29 WO claimed
CN-103764140-A Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases KOREA RES INST CHEM TECH 2014-04-30 CN claimed
WO-2013157022-A1 SUBSTITUTED HETERO-BICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF ADVINUS THERAPEUTICS LIMITED (IN) 2013-10-24 WO claimed
WO-2011146287-A1 PYRAZOLO[4,3-B]PYRIDINE-7-AMINE INHIBITORS OF ALK5 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-11-24 WO claimed
CN-101072561-A Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS INC (US) 2007-11-14 CN claimed
EP-1250332-A1 INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION Abbott Laboratories (US) 2002-10-23 EP claimed
WO-2001044223-A1 INHIBITORS OF INTERLEUKIN 5 GENE EXPRESSION ABBOTT LABORATORIES (US) 2001-06-21 WO claimed
EP-4608817-A1 COMPOUNDS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-09-03 EP disclosed
EP-0185964-A2 Dihydropyridine-carboxylic acid amides, process for their preparation and their use in medicaments BAYER AG (DE) 1986-07-02 EP disclosed